Results 101 to 110 of about 797 (141)

Imminent fracture risk: contributing mechanisms, risk assessment, and implications for treatment.

J Clin Endocrinol Metab
Vilaca T, Eastell R.
europepmc   +1 more source

Fahr's Syndrome Secondary to Hypoparathyroidism Presenting With Neurological and Cardiac Manifestations. [PDF]

Cureus
Elliott I, Dalvi S, Leong K, Wong S.
europepmc   +1 more source

Positron Emission Tomography-Computed Tomography (PET-CT) Diagnosis of Large-Vessel Giant Cell Arteritis Presenting as Pyrexia of Unknown Origin Without Classical Cranial Features: A Case Report. [PDF]

Cureus
Hameed A, Gaunekar SA, Haroun N, Kakarla J, Mehmood Y, Raoof A.   +5 more
europepmc   +1 more source

Sternal haematoma infusion catheter: a novel technique for pain management in manubriosternal fractures in the emergency department. [PDF]

Anaesth Rep
Frowde K, Naeem S, Alzarrad A, Abdel-Aziz D, Schofield OW.   +4 more
europepmc   +1 more source

Healthcare utilization patterns and medication burden in post-COVID syndrome: a cross-sectional analysis reveals four phenotypes. [PDF]

Front Health Serv
Hamberger J, Kraus L, Meissner K, Hinterberger T, Loew T, Schoeffski O, Gündel H, Walter S, Jarczok MN, Weimer K.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Alendronate/Colecalciferol

Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005
Alendronate/colecalciferol 70 mg/2800 IU, a once-weekly tablet containing the bisphosphonate alendronate and colecalciferol (the precursor of the biologically active form of vitamin D), has been approved for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis.
Monique P Curran
exaly   +3 more sources